A Phase I and Randomized Phase II Double Blinded Placebo Controlled Study of mFOLFOX6 +/- AMG 337 in the First Line Treatment of Patients With Her2/Neu Negative and High MET Expressing Advanced Gastric and Esophageal Adenocarcinoma
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 25 Oct 2017
At a glance
- Drugs AMG 337 (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Oct 2017 Planned End Date changed from 1 Jun 2016 to 6 Mar 2020.
- 17 Oct 2017 Planned primary completion date changed from 1 Jun 2016 to 6 Mar 2018.
- 17 Oct 2017 Planned initiation date changed from 1 Jan 2015 to 6 Mar 2015.